Human Umbilical Mesenchymal Stem

The project focuses on leveraging stem cell technology to collaborate with hospitals for the treatment of anti-aging and chronic diseases such as erectile dysfunction (ED) and diabetes., Our team is a leading team in stem cell therapy and clinical transformation, with extensive experience in developing innovative stem cell treatments and collaborating with top medical institutions.

Application Scenarios

Men's Health

Treatment of erectile dysfunction (ED), promote tissue repair and enhance erectile function

Anti-Aging

Rejuvenate skin, reduce wrinkles, and improve overall skin quality, providing a non-invasive solution for anti-aging

Diabetes Treatment

Manage and potentially reverse complications associated with diabetes, improving patients' quality of life

Other Chronic Diseases

Cardiovascular diseases, joint disorders, and other chronic conditions, offering new hope for patients with limited treatment options

About Products

Our stem cell product is based on sub-pluripotent stem cells, a breakthrough type of adult stem cell with the following attributes:

High Pluripotency: Differentiation potential comparable to embryonic stem cells, enabling versatile tissue regeneration.

Safety: Matches the safety profile of normal somatic cells, avoiding ethical controversies and safety concerns associated with embryonic stem cells.

Immunomodulatory Function: Dual-directional regulation capability, promoting immune balance by inducing regulatory dendritic cells (DCs) and mitigating hyperinflammatory responses.

Scalable Production: Developed using engineered preparation processes to ensure large-scale production with consistent quality.

Therapeutic Versatility: Addressing medical needs in immune disorders, organ rejection, and chronic inflammatory diseases.

This product is the first stem cell-based new drug approved for clinical trials globally, laying the foundation for innovative approaches in regenerative medicine and immunotherapy.

Patent

The project is supported by a comprehensive portfolio of intellectual property, including:

• First-In-Class Discovery: A patent for the isolation and identification of sub-pluripotent stem cells, a novel adult stem cell population with high pluripotency and unmatched safety.

  
  

• Core Technologies: Patents related to scalable production processes, immunomodulatory function induction, and quality control for stem cell therapy.

  
  

• Innovative Techniques: Intellectual property covering seed stem cell acquisition, characterization, and engineered preparation methods, essential for clinical and commercial applications.

Clinical Resources

• National Clinical Pharmacology Centers: Trials conducted at leading institutions such as Peking University People’s Hospital, Peking Union Medical College Hospital, PLA 301 Hospital, and Zhejiang University Medical College’s First Affiliated Hospital.

  
  

• Extensive Clinical Trials: Over 11 years of rigorous testing to demonstrate the safety, efficacy, and consistency of the stem cell product.

  
  

• Collaborative Network: Partnerships with top-tier hospitals and research centers to ensure the reliability of clinical data and streamline the approval process.

Certifications

• Clinical Trial Approval: In 2004, the product became the first stem cell-based new drug globally to receive regulatory approval for clinical trials.

  
  

• Quality Standards: Developed China’s first quality standard for stem cell products, ensuring compliance with both national and international benchmarks.

  
  

• Recognition by Regulatory Bodies: Approved by the National Food and Drug Administration (CFDA) with new drug approval numbers 2004L04792 and 2006L01037, highlighting its regulatory credibility.

Advantages of Project

• Proprietary "ready-to-use"

ensure high quality and bioactivity.

• High secretion of growth factors promoting vascular and neural regeneration

critical for treating ED and other conditions.

• Established quality control systems

compliant with national standards for clinical and pharmaceutical-grade stem cell products

• Extensive research

demonstrates the safety and efficacy of hUC-MSCs in treating ED, diabetes, and other conditions.

• Advanced stem cell preparation and preservation techniques

including the use of serum-free culture mediums and cryopreservation methods suitable for -80°C storage

• High demand for innovative treatments for chronic diseases and anti-aging solutions

growing global market for stem cell therapy, with significant investment and research driving rapid industry expansion